Castrate Resistant Prostate Cancer Clinical Trials
43 clinical trials for Castrate Resistant Prostate Cancer across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer — RECRUITING · PHASE2
- A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies — RECRUITING · PHASE1
- 177Lu-HTK03170 in mCRPC With PSMA Positive Disease — RECRUITING · PHASE1
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas — RECRUITING · PHASE1
- TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors — RECRUITING · PHASE1
- Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer — RECRUITING
- Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies — RECRUITING · PHASE1
- An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer — COMPLETED · PHASE3
- Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide — COMPLETED · PHASE2
- NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors — TERMINATED · PHASE1
- Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer — WITHDRAWN · PHASE2
- Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA — ACTIVE_NOT_RECRUITING · PHASE2
- Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer — TERMINATED · PHASE2
- Checkpoint Inhibitors and SBRT for MCRPC — COMPLETED · PHASE2
- An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer — TERMINATED · PHASE2
- Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage — OTHER · PHASE2
- Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients — WITHDRAWN · NA
- LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer — SUSPENDED · PHASE1
- A Study of PRT2527 in Participants With Advanced Solid Tumors — COMPLETED · PHASE1
- Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer — TERMINATED · PHASE1
- Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) — COMPLETED · PHASE1
- PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer — COMPLETED · PHASE1
- Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors — TERMINATED · PHASE1
- Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers — WITHDRAWN · PHASE2
- A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) — TERMINATED · PHASE2
- Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas — OTHER · PHASE1
- Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC — WITHDRAWN · PHASE1
- Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone — WITHDRAWN · PHASE1
- Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223 — COMPLETED
- A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) — COMPLETED · PHASE1
- Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer — COMPLETED · PHASE2
- MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer — COMPLETED · PHASE1
- Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor — COMPLETED · PHASE1
- Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer — COMPLETED · PHASE3
- PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy — COMPLETED · PHASE1
- A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer — TERMINATED · PHASE1
- Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer — COMPLETED · PHASE1
- Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy — TERMINATED · PHASE2
- A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) — TERMINATED · PHASE3
- Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer — COMPLETED · PHASE3
- Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer — TERMINATED · PHASE1
- Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients — TERMINATED · PHASE1
- AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer — COMPLETED · PHASE1
Refine this search